vapreotide

08/01/2013 - "In the A549-hSSTR2 xenograft tumor group, the growth of the tumors treated with (131)I-RC-160 was significantly inhibited as compared to tumors in the group treated with RC-160 (P < 0.01). "
08/01/2013 - "The inhibitory effects of (131)I-RC-160, RC-160, and Na(131)I on the tumors were recorded by measuring the tumor volumes. "
11/01/2010 - "Furthermore, treatment fractionation group (2 × 7.4 MBq (188)Re-RC-160), induced significantly increased tumor-growth inhibition compare with single 7.4 MBq (188)Re-RC-160 treatment (P<.05). "
04/01/2010 - "In vivo radioimaging revealed specific targeting of RC-160 to the tumors derived from pCIS-A549 cells when compared to those from control A549 cells. "
07/14/2006 - "SST5-mediated inhibition of nNOS activity was demonstrated to be essential to the RC-160 anti-proliferative effect on pancreatic endocrine tumor-derived cells. "

01/01/2003 - "Hemodynamic effects of acute and chronic administration of vapreotide in rats with cirrhosis."
04/01/2008 - "The pivotal study of early administration of vapreotide in patients with cirrhosis and variceal bleeding has shown a significant improvement in bleeding control and, in the subset of patients with significant bleeding, a significant reduction in mortality. "
01/04/2001 - "In patients with cirrhosis and variceal bleeding, the combination of vapreotide and endoscopic treatment is more effective than endoscopic treatment alone as a method of controlling acute bleeding. "
10/01/2009 - "These findings endorse the need for future trials to evaluate vapreotide and its use in acute variceal hemorrhage, a morbidity among patients with cirrhosis."
01/01/2003 - "[Early administration of vapreotide for variceal bleeding in patients with cirrhosis]."

10/01/2009 - "Vapreotide appears to have benefit in the control of acute variceal bleeding. "
10/01/2009 - "This paper reviews the literature regarding the basic science and clinical efficacy of vapreotide in acute variceal bleeding. "
10/01/2009 - "Recently, vapreotide has been studied in patients to evaluate its efficacy as treatment for acute variceal hemorrhage. "
07/01/2002 - "Vapreotide in variceal bleeding."
01/04/2001 - "During the five-day infusion, the primary objective--survival and control of bleeding--was achieved in 65 of 98 patients in the vapreotide group (66 percent) as compared with 49 of 98 patients in the placebo group (50 percent) (P=0.02). "

11/01/2000 - "Phase III trials have been initiated in France, investigating the utility of vapreotide in the treatment of prostate cancer. "
07/01/2006 - "Some endocrine studies with early analogs of somatostatin were also cited and a clinical trial with somatostatin analog vapreotide in patients with relapsed prostate cancer was reviewed. "
07/01/2000 - "The affinity and density of binding sites for SST analog RC-160 on 80 surgical specimens of prostate cancers were determined by ligand competition assays. "
05/01/1992 - "RC-101-I showed higher binding affinity to somatostatin-14 receptors than RC-160 in human breast, pancreatic, and prostate cancer. "
12/20/1990 - "In vivo administration of analog RC-160 inhibits the growth of Dunning R-3327 prostate cancers in rats, MXT mammary tumors in mice and BOP-induced ductal pancreatic cancers in hamsters. "

09/01/1992 - "We conclude that lack of receptors accounts for the failure of SS-14 and RC-160 to influence the growth of human pancreatic cancer in vitro. "
05/15/1990 - "This higher dose of RC-160 exerted a greater suppressive effect on pancreatic cancers than the regimens previously used (5-25 micrograms/day). "
01/01/2000 - "The antiproliferative activity of lipophilized derivatives of RC-160 on the growth of MIA-PaCa2 (human pancreatic carcinoma), DU145 (human prostate carcinoma), ECV304 (human umbilical chord endothelioma), as well as their antiangiogenic activity was evaluated in vitro. "
07/01/2002 - "We examined whether TT-232 had antiproliferative activity in human pancreatic cancer cell lines, and compared its antiproliferative activity with that of RC-160 and other TT-232 derivatives. "
08/01/1999 - "RC-160 decreased the number of EGF receptors on pancreatic cancers by 31% 3 h after administration, but the receptors had returned to normal level at 6 h. "